
|Videos|July 21, 2022
How Ruxolitinib Will Change the Future of Vitiligo Treatment
Author(s)Kaitlyn Bader, Associate Editor
Pearl Grimes, MD, FAAD, and director of the Grimes Center of Medical and Aesthetic Dermatology and the Vitiligo & Pigmentation Institute of Southern California in Los Angeles, explains why the FDA approval of ruxolitinib cream 1.5% is monumental in the treatment of vitiligo.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Addressing Delays in Prior Authorization Processes That Negatively Impact Patients
2
Meta-analysis Confirms Benefits of Roflumilast 0.3% Cream for PsO
3
Transformative Advances This Year and Beyond
4
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
5


















